In:
Chemotherapy, S. Karger AG, Vol. 54, No. 6 ( 2008), p. 479-484
Abstract:
〈 i 〉 Background: 〈 /i 〉 Biliary tract cancers are among the most aggressive tumors with a poor prognosis. We conducted a phase II study on combination chemotherapy consisting of S-1 and oxaliplatin in previously untreated patients . 〈 i 〉 Methods: 〈 /i 〉 Patients were treated with S-1 40 mg/m 〈 sup 〉 2 〈 /sup 〉 twice daily, administered orally on days 1–28, and 85 mg/m 〈 sup 〉 2 〈 /sup 〉 of oxaliplatin, administered via an intravenous 90-min infusion on days 1, 15 and 29. Treatments were repeated every 6 weeks. 〈 i 〉 Results: 〈 /i 〉 15 patients were enrolled: 9 patients (60%) had intrahepatic and 3 (20%) had extrahepatic cholangiocarcinoma, 2 (13.3%) had cancer of the ampulla of Vater and 1 patient had gall bladder cancer. Partial response was observed in 1 of the 15 (6.7%) patients. Stable disease was observed in 4 patients (26.7%). The median time to progression was 1.4 months (95% confidence interval, CI, 0.9–1.9), and the median overall survival was 3.1 months (95% CI, 0.0–7.0). Grade 3 hematologic toxicities included neutropenia (1, 6.7%) and thrombocytopenia (1, 6.7%). As the response rate in stage I did not justify progression to stage II (≧2/15), this study had to be discontinued in accordance with the established protocols. 〈 i 〉 Conclusion: 〈 /i 〉 The combination chemotherapy with S-1 and oxaliplatin utilized in this study resulted in no promising antitumor activity.
Type of Medium:
Online Resource
ISSN:
0009-3157
,
1421-9794
Language:
English
Publisher:
S. Karger AG
Publication Date:
2008
detail.hit.zdb_id:
1482111-4
SSG:
15,3
Permalink